IDEAS home Printed from https://ideas.repec.org/a/adp/jctoij/v9y2018i4p99-101.html
   My bibliography  Save this article

Olaparib: A Tale of Two Dosage Forms

Author

Listed:
  • Trevor N Christ

    (Department of Pharmacy, University of Chicago Medical Center, USA)

Abstract

Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor approved by the FDA, with three approvals in two different cancer types. The original dosage form of olaparib was a 50 mg capsule, requiring 16 capsules per day for patients at full dose therapy which prompted development of a tablet dosage form with improved bioavailability. Herein, major trials for olaparib are reviewed and the two dosage forms are compared from a pharmacokinetic and clinical perspective.

Suggested Citation

  • Trevor N Christ, 2018. "Olaparib: A Tale of Two Dosage Forms," Cancer Therapy & Oncology International Journal, Juniper Publishers Inc., vol. 9(4), pages 99-101, January.
    • Handle: RePEc:adp:jctoij:v:9:y:2018:i:4:p:99-101
    DOI: 10.19080/CTOIJ.2018.09.555766
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555766.pdf
    Download Restriction: no
    File URL: https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555766.php
    Download Restriction: no
    File URL: https://libkey.io/10.19080/CTOIJ.2018.09.555766?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jctoij:v:9:y:2018:i:4:p:99-101. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.